14 November (Day 2)
Session
3. Business of Cell & Gene Therapy
Chair:
Steve Oh, Bioprocessing
Technology Institute, Singapore
08:30-08:50 Developing
allogeneic cellular immunotherapies with iPSC technology
Wen Bo Wang, Fate Therapeutics, USA
08:50-09:10 Radically
simplifying scale-up and clinical translation of hMSCs
and extracellular vesicles
Mayasari Lim, RoosterBio Inc, USA
09:10-09:25 Short talk: Characterization and application
of size-dependent mesenchymal stem cell subpopulations separated using
label-free microfluidics
Yin
Lu, Singapore-MIT Alliance in Research and Technology, Singapore
Arthur
Sampaio, STEMCELL Technologies, Canada
`
09:45-10:05 Development
of an injectable cartilage gel using chondrogenic progenitor cells
Bryan Choi, ATEMs, Korea
10:05-10:35 MORNING TEA BREAK
10:35-10:55 Commercialization of advanced allogeneic cell
therapy product in Korea and beyond
Antonio Lee, Medipost, Korea
10:55-11:15 Continuous bioprocessing platform for CAR T
Xiangliang Lin, Esco
Aster, Singapore
11:15-11:35 The patient in the incubator: the cytocentric approach to avoiding suboptimal transients
Alicia Henn, Biospherix
Ltd, USA
11:35-11:55 Pooled mesenchymal stromal cells – a
potential break through therapy for critical limb ischemia (CLI) Management
Pawan
Gupta, Stempeutics, India
11:55-12:35 Panel discussion
Panellists: B Levine, M Lim,
A Sampaio, B Choi, XL Lin, A Henn, P Gupta
Moderators: WB Wang & T
Lee
12:35-14:00 LUNCH BREAK
Session
4. Responsible Pathways to Translation with Cell Therapies
Chair:
Tamra Lysaght, National
University of Singapore
14:00-14:05 Introduction
Tamra Lysaght, National University of
Singapore, Singapore
14:05-14:25 The
use of professional disciplinary systems to regulate innovation: lessons from
stem cell practice in Australia
Cameron Stewart, University of Sydney,
Australia
14:25-14:45 The oversight of clinical innovation in a
medical marketplace
Wendy Lipworth, University of Sydney,
Australia
14:45-15:05 Expedited
regulatory pathways for stem cell-based products in Malaysia: ethical and legal
considerations
Mohammad
Firdaus Bin Abdul Aziz, University of Malaya, Malaysia
15:05-15:20 Short Talk: Autologous cell treatments: who owns the cells?
Patrick
Foong, Western Sydney University, Australia
15:20-15:40 Regulatory
updates on cell and gene therapy products in Singapore
Lee Lee Ong, Health
Sciences Authority, Singapore
15:40-16:10 AFTERNOON TEA BREAK (hosted by BIOSPHERIX)
16:10-16:30 Making the unproven proven
Mickey Koh, St George’s Hospital, UK
16:30-17:20 Panel discussion
Panellists:
C Stewart, W Lipworth, F Aziz, P Foong, LL Ong, M Koh
Moderator: T Lysaght
17:20-18:05 KEYNOTE LECTURE (Chair: Ray Dunn, IMB,
Singapore)
The evolution and challenges introducing
cell-based therapies into burn care and scar therapy
Fiona Wood, Royal Perth
Hospital, Australia
18:05-20:00 POSTER SESSION WITH
WINE & CHEESE
END OF THE DAY 2
Jointly Organized by:
|
|